A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)

• Status: Recruiting
• Trial end date: 2025-02-01

Summary

This study is a Phase 1, open-label, single institution, dose escalation and dose expansion study to evaluate the efficacy, safety, and tolerability of APX005M in combination with nivolumab and ipilimumab in patients with advanced melanoma and RCC.

• Phase: Phase 1

Details

• Lead Sponsor: Yale University
• Collaborator: Apexigen, Inc.
• Treatments: Ipilimumab; Nivolumab